abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

10 Feb 2010

Rupali Mukherjee, Times of India

Court rejects Bayer's appeal [India]

In a relief to generic companies and promoting consumers' access to affordable treatment, the Delhi high court dismissed an appeal by...Bayer Corporation, which sought patent linkage — linking regulatory approval of generic medicines with their patent status... A division bench of Delhi high court on Tuesday dismissed Bayer's appeal against a judgment on an anti-cancer drug... Patent linkage is against public health interests as it will delay the entry of cheaper generic medicines into the market... Anand Grover, counsel for Cancer Patient Aid Association (CPAA) told TOI: "The patent system and drug regulatory system are two separate and independent mechanisms...If introduced, the patent linkage system would have seriously impacted the early entry of generic drugs into the market..."